drugset / Trial / NCT05733624

Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis

NCT05733624

Phase 2 Completed 116 enrolled SCAI Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.

Timeline

Start
2023-01-05
Primary completion
2023-08-23
Completion
2024-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 0.01 % Topical
Subject Cyclosporine Peptide 0.02 % Topical
Subject Cyclosporine Peptide 0.05 % Topical

Indications